Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03416829 · ClinicalTrials.gov registry record · NA
Preliminary Study 1 to Test the Effects of Ambulatory Voice Biofeedback
A NA study of Vocal Fold Nodules, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT03416829 is a NA study of Vocal Fold Nodules that has completed, run by Massachusetts General Hospital. The registered enrollment target is 29 participants, below the 55-participant average among 3 other Vocal Fold Nodules trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03416829, a NA study of Vocal Fold Nodules, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This first study will enroll 3 groups of patients with vocal fold nodules that will receive different schedules of ambulatory voice biofeedback (100% frequency feedback, 25% frequency feedback, summary feedback) to avoid their upper 15th percentile of vocal loudness.
Conditions Studied
Interventions
- BEHAVIORAL Ambulatory voice biofeedback
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Center for Laryngeal Surgery and Voice Rehabilitation - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03416829
The ClinicalTrials.gov registry entry for NCT03416829 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 3 other Vocal Fold Nodules trials with a reported enrollment target (47% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vocal Fold Nodules appearing as the primary indexed condition, and to 1 intervention - of which Ambulatory voice biofeedback is the first listed.
NCT03416829 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03416829 about?
NCT03416829 is a clinical study titled "Preliminary Study 1 to Test the Effects of Ambulatory Voice Biofeedback". This first study will enroll 3 groups of patients with vocal fold nodules that will receive different schedules of ambulatory voice biofeedback (100% frequency feedback, 25% frequency feedback, summary feedback) to avoid their upper 15th percentile of vocal loudness.
What is the current status of trial NCT03416829?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2017-09-27. Estimated completion is 2022-06-30.
What conditions does trial NCT03416829 study?
This clinical trial studies the following conditions: Vocal Fold Nodules.
What interventions are being tested in trial NCT03416829?
The interventions under investigation include: Ambulatory voice biofeedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT03416829?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03416829 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vocal Fold Nodules
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.